Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model
- PMID: 18060082
- PMCID: PMC2100369
- DOI: 10.1371/journal.pntd.0000034
Optimization of topical therapy for Leishmania major localized cutaneous leishmaniasis using a reliable C57BL/6 Model
Abstract
Background: Because topical therapy is easy and usually painless, it is an attractive first-line option for the treatment of localized cutaneous leishmaniasis (LCL). Promising ointments are in the final stages of development. One main objective was to help optimize the treatment modalities of human LCL with WR279396, a topical formulation of aminoglycosides that was recently proven to be efficient and safe for use in humans.
Methodology/principal findings: C57BL/6 mice were inoculated in the ear with luciferase transgenic L. major and then treated with WR279396. The treatment period spanned lesion onset, and the evolution of clinical signs and bioluminescent parasite loads could be followed for several months without killing the mice. As judged by clinical healing and a 1.5-3 log parasite load decrease in less than 2 weeks, the 94% efficacy of 10 daily applications of WR279396 in mice was very similar to what had been previously observed in clinical trials. When WR279396 was applied with an occlusive dressing, parasitological and clinical efficacy was significantly increased and no rebound of parasite load was observed. In addition, 5 applications under occlusion were more efficient when done every other day for 10 days than daily for 5 days, showing that length of therapy is a more important determinant of treatment efficacy than the total dose topically applied.
Conclusions/significance: Occlusion has a significant adjuvant effect on aminoglycoside ointment therapy of experimental cutaneaous leishmaniasis (CL), a concept that might apply to other antileishmanial or antimicrobial ointments. Generated in a laboratory mouse-based model that closely mimics the course of LCL in humans, our results support a schedule based on discontinuous applications for a few weeks rather than several daily applications for a few days.
Conflict of interest statement
HL, SG, GG, GMi and TL declare that no competing interests exist. PB and GMo were co-investigators in a Phase 2 clinical trial of WR279396 conducted under the co-sponsorship of the Office of The Surgeon General, Department of the Army, FDA IND number 50,098, HSRRB Protocol number A-97-68.1, and the Institut Pasteur, Paris, France. Their institution (Institut Pasteur) was awarded a grant from US Army Medical Research and Materiel Command (MRMC) for the execution of this clinical trial. MRMC is responsible for the development of WR279396.
Figures





References
-
- Desjeux P. Worldwide increasing risk factors for leishmaniasis. Medical Microbiology&Immunology. 2001;190:77–79. - PubMed
-
- Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends in Parasitology. 2006;22:552–557. - PubMed
-
- Buffet P, Morizot G. Cutaneous leishmaniasis in France: towards the end of injectable therapy? Bull Soc Pathol Exot. 2003;96:383–388. - PubMed
-
- Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 2005;19:241–266. - PubMed
-
- Bryceson A. Therapy in man. In: Peters W, Killick-Kendrick R, editors. The leishmaniases. London: Academic Press; 1987. pp. 847–869.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials